ALDH1A3 reduction rendered the breast cancer cells vulnerable to glycolysis inhibition with inhibitor 2-deoxy-D-glucose (2DG), which reduced the increased CD24−CD44+ population, migration, ROS, glycolysis, tumor growth, and tumor initiation potential. Here, ALDH1A3 is linked to breast cancer.